Artiva Halts AlloNK and Cuts 94% of Workforce Amid Strategic Options Review
Key Facts
Artiva Biotherapeutics announced on October 27 that it would halt development of its AlloNK (AB-101) product candidate and approved a plan to cut about 94% of its workforce, shifting the company’s focus to a review of strategic alternatives. The company said longer-term follow-up data did not show clinical response durability at the level it considers necessary to continue development. It added that B-cell depletion and clinical response data remained consistent with previously announced results. The board had approved the decision to halt development of the candidate and the workforce reduction plan on October 22. The decision included not starting the planned pivotal Phase 3 trial, as well as discontinuing further dosing in ongoing studies.
The decision to halt the program was also linked to a review of safety events in a Phase 2a trial. One participant died after developing leukoencephalopathy following treatment; the investigator and an independent safety reviewer assessed the case as likely related to fludarabine neurotoxicity. The U.S. Food and Drug Administration requested a suspension of enrollment and dosing in the study. In a separate case, another participant died suddenly about two months after starting treatment. The investigator assessed that death as unrelated to AlloNK or any other component of the treatment regimen, while its cause remained undetermined.
Artiva said it would not give additional doses to patients participating in ongoing AlloNK studies and would not start the planned pivotal Phase 3 trial. It will coordinate the program’s closure with the Food and Drug Administration, investigators and institutional review boards. The company said required safety follow-up will continue during the closure process. It also canceled the clinical data presentation scheduled for the ACR Convergence 2026 conference. It also canceled an investor webcast scheduled for November 9, 2026, with updated data potentially to be presented at later scientific meetings depending on the outcome of the alternatives review.
The company is considering a range of options, including a merger or business combination, an asset sale or licensing, and dissolution and liquidation. It has retained Leerink Partners as financial adviser to the process. The company gave no assurance that a transaction would be completed or that the review would produce a specific outcome. It said it does not intend to update the market unless the board approves a specific path, the process concludes or an additional disclosure becomes necessary. The company estimates the workforce reduction will be completed in the first quarter of 2027, while the vast majority of business-reduction costs are expected to be recorded in the fourth quarter of 2026, with no current estimate of the total costs and charges.
According to the company’s disclosure, business-reduction costs primarily relate to contract terminations, the discontinuation of clinical trials, leases and existing obligations, operational wind-down activities, and employee reductions. On September 30, 2026, cash, cash equivalents and investments totaled about $319.1 million, according to a preliminary, unaudited estimate subject to adjustment. Artiva reported a net loss of $25.0 million in the second quarter of 2026, compared with a loss of $21.3 million in the same period of 2025. It used $41.3 million in cash for operating activities in the first half of 2026, compared with $42.8 million in the first half of 2025. The company said in its quarterly report that it has incurred net losses and negative operating cash flows since inception and expects to continue incurring losses for the foreseeable future.
In May 2026, Artiva raised $300.0 million gross through a public offering and the issuance of pre-funded warrants, with net proceeds after costs of $282.7 million. The company’s shares closed at $4.28 on October 28, according to EL7 data. The workforce reduction announcement is part of a broad plan to reduce the current workforce, while the company has not disclosed total wind-down costs. The alternatives review puts the fate of the company’s assets and programs at the center of the next phase. The most distant operational timeline set by the company is the expected completion of the workforce reduction in the first quarter of 2027.